Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released May 5, 2021, after the close
10-Q filed May 5, 2021, 35 days after period end · 0001558370-21-005903
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $81.02M | $55.76M | $12.62M | — |
| Net Income | $39.50M | $21.24M | -$17.60M | -$24.39M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| $0.22 |
| $0.13 |
| -$0.11 |
| -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
